

Plamotamab

Cat. No.:	HY-P99776
CAS No.:	2138442-31-4
Target:	CD20; CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo ^{[1][2]} .
In Vitro	Plamotamab induces the killing of endogenous B cells and activation of endogenous CD8 ⁺ T cells within human PBMCs in vitro, with an EC ₅₀ value of 0.113 nM ^[2] . Plamotamab induces T cell-mediated killing in Raji tumor cells in vitro, with an EC ₅₀ value of 0.144 nM ^[2] . Plamotamab binds to CD3δ/ε, CD3 ⁺ T cells, CD4 ⁺ T cells, CD8 ⁺ T cells, B cells, Raji cells, with EC ₅₀ s of 2.1 nM, 11.78 nM, 10.12 nM, 200.3 nM, and 134.8 nM, respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Plamotamab (0.17 mg/kg; i.p.) causes tumor growth suppression in human PBMC-engrafted mouse model containing Raji xenograft ^[2] . Plamotamab (0.3 mg/kg; i.p.) leads to cytokine release in cynomolgus monkeys, indicating a safety to be improved ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Parrondo RD, et al. Plamotamab (XmAb[®]13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.

[2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA